ArticlePloS one2026
Ceftibuten-polymyxin B combination alters resistance and cell wall gene expression in multidrug-resistant Klebsiella pneumoniae.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultidrug-resistant Klebsiella pneumoniae, including carbapenem- and polymyxin-resistant strains, poses a major public health threat by severely limiting therapeutic options. Although ceftibuten (CTB) and polymyxin B (PMB) show evidence of synergistic activity, their mechanisms of action remain unclear. In this context, this study evaluated the combined effect of CTB and PMB on the expression of genes involved in cell wall synthesis and antimicrobial resistance in K. pneumoniae.
methodsProtein sequences of selected resistance- and cell wall-related genes were retrieved from UniProt and analyzed in silico for conserved domains, motifs, localization (PSORTb), and pathways (KEGG). The effects of CTB/PMB, alone and in combination, were evaluated on the expression of genes involved in cell wall synthesis regulation (ftsL, dacA, and dacC) and antimicrobial resistance mechanisms (pagP, pagL, ampC). The 16s gene was used as endogenous control. Bacterial cultures (1.5 × 106 CFU/mL) were incubated with CTB/PMB, PMB and CTB at 0.5× and 1 × minimum inhibitory concentrations (MIC) for 2 and 4 h, followed by mRNA extraction and gene expression analysis through qRT-PCR.
resultsIn silico analyses revealed that pagP and pagL contain conserved domains associated with lipid A modification, while ampC and ftsL showed class C β-lactamase domains. DacA and dacC were linked to the PRK13482 domain of the cl44310 superfamily. Predicted localizations placed pagP/pagL in the outer membrane, ampC in the periplasm, and ftsL/dacA/dacC in the cytoplasmic membrane. KEGG annotation indicated that ftsI, dacC, ampC, and rtxB participate in essential pathways, including peptidoglycan biosynthesis and β-lactam resistance, highlighting their physiological and clinical relevance in K. pneumoniae. After 2 h of exposure, no significant changes were observed in the expression of the selected genes. However, after 4 h, dacA, ftsL, and pagP expression levels significantly increased in all groups treated with CTB/PMB. Additionally, dacC and pagL expression were upregulated in the group treated with the combination at 1 × MIC.
conclusionsThus, combined CTB/PMB exposure was associated with modulation of gene expression involved in cell wall synthesis and antimicrobial resistance, suggesting transcriptional adaptive responses under antimicrobial pressure. These findings provide preliminary molecular insights into the response of multidrug-resistant K. pneumoniae to CTB/PMB exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.